Pazopanib/Pazopanib manufacturer

Pazopanib is produced by Novartis Pharmaceuticals of Switzerland. Pazopanib tablets are suitable for the treatment of advanced renal cell carcinoma (RCC) in adults. Pazopanib tablets are also indicated for the treatment of adult patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy.

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential anti-tumor activity. Pazopanib is a synthetic indazolylpyrimidine with a steady-state concentration greater than 15 μg/ml. This concentration is sufficient to observe maximal inhibition of VEGFR2 phosphorylation and some antitumor activity (the concentration required to inhibit the receptor is 0.01 - 0.084 μmol/L). Reduced tumor blood flow, increased tumor cell apoptosis, tumor growth inhibition, reduced tumor interstitial fluid pressure, and cancer cell hypoxia were observed in treated patients. Pazopanib is a second-generation multi-target tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors -1, -2 and -3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β and c-kit. These receptor targets are part of the angiogenic pathway, which promotes the formation of tumor blood vessels for tumor survival and growth. Cancer patients mainly excrete through feces (82.2%) and a small amount through urine (4%). Most of the administered dose is excreted unchanged from the body. Approximately 10% of the dose are oxidative metabolites, most of which are excreted in the feces. There are generic drugs in Bangladesh, and the retail price of Bangladesh Yaopin International Pharmaceuticals is about 200mg 30 tablets 600 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.